Novel Experimental Agents for the Treatment of Hypercholesterolemia

Novel Experimental Agents for the Treatment of Hypercholesterolemia

Ivan Pećin,1,2 Željko Reiner1,2 1Zagreb School of Medicine, University of Zagreb, Zagreb, Croatia; 2Division of Metabolic Diseases, Department of Internal Medicine, University Hospital Center, Zagreb, CroatiaCorrespondence: Željko ReinerDivision of Metabolic Diseases, Department of Internal Medicine...

Full description

Bibliographic Details
Main Authors:	Pećin I, Reiner Ž
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-02-01
Series:	Journal of Experimental Pharmacology
Subjects:	dyslipidemia novel hypolipemic drugs cardiovascular risk ldl-cholesterol triglycerides inclisiran pcsk9 inhibitors pemafibrate bempedoic acid angptl3 pelacarsen
Online Access:	https://www.dovepress.com/novel-experimental-agents-for-the-treatment-of-hypercholesterolemia-peer-reviewed-fulltext-article-JEP

Similar Items

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
by: Constantine E. Kosmas, et al.
Published: (2018-07-01)

Low-density lipoprotein cholesterol lowering treatment: the current approach
by: Irina Crismaru, et al.
Published: (2020-05-01)

Is lower better? Is lowest the best?
by: Lale Tokgözoğlu
Published: (2017-04-01)

Editorial: Genetics of Familial Hypercholesterolemia: New Insight
by: Alpo Vuorio, et al.
Published: (2021-05-01)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
by: Piotr Pęczek, et al.
Published: (2021-05-01)

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
by: Chang-Wook Nam, et al.
Published: (2019-11-01)

Prevalence, self-awareness, and LDL cholesterol levels among patients highly suspected as familial hypercholesterolemia in a Japanese community
by: Hayato Tada, et al.
Published: (2020-11-01)

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
by: Kosmas CE, et al.
Published: (2020-10-01)

Bempedoic acid for the treatment of dyslipidemia
by: Joel C Marrs, et al.
Published: (2020-08-01)

Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels
by: Chuantao Jiang, et al.
Published: (2018-02-01)

Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
by: Angela Dardano, et al.
Published: (2021-07-01)

What is new regarding the treatment of dyslipidemia in the 2019 European Society of Cardiology Guidelines?
by: Madalina A. MUNTEANU, et al.
Published: (2019-12-01)

Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials
by: Ajay K Shukla, et al.
Published: (2019-01-01)

Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study
by: Ichiro Komiya, et al.
Published: (2021-02-01)

PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
by: Ioanna Andreadou, et al.
Published: (2020-11-01)

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans
by: Jeffrey D. Browning, et al.
Published: (2010-11-01)

Asociation of PCSK9 with Low Density Lipoproteins (LDL) in the Regulation of LDL-Cholesterol Levels
by: Sarkar, Samantha Khadija
Published: (2015)

A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
by: Rana K, et al.
Published: (2019-09-01)

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
by: Jason S. Troutt, et al.
Published: (2010-02-01)

Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence
by: Keshav Kumar Gupta, et al.
Published: (2018-12-01)

Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice
by: Jean-Mathieu Berger, et al.
Published: (2017-08-01)

Correlation of PCSK9 and Serum sdLDL Levels and Other Demographic and Laboratory Indicators in Healthy Individuals
by: Reza Hosseini-Fard, et al.
Published: (2018-05-01)

Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients
by: Ulrich Julius
Published: (2018-05-01)

Pediatric dyslipidemia in a minority mostly-immigrant inner city population
by: Matthias Manuel, et al.
Published: (2019-08-01)

New Drugs for Treating Dyslipidemia: Beyond Statins
by: Chang Ho Ahn, et al.
Published: (2015-04-01)

New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
by: Qidi Ying, et al.
Published: (2021-02-01)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
by: A. A. Shikaleva, et al.
Published: (2021-01-01)

The Functional Characterization of PCSK9's Binding Interactions with LDL and the LDL Receptor
by: Matyas, Angela
Published: (2020)

Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives
by: Kyung Hoon Cho, et al.
Published: (2020-09-01)

Neoagarooligosaccharides enhance the level and efficiency of LDL receptor and improve cholesterol homeostasis
by: Ji Hye Yang, et al.
Published: (2017-11-01)

Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
by: Michel Farnier
Published: (2008-10-01)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
by: Ioanna Gouni-Berthold, et al.
Published: (2014-12-01)

PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01)

Effect of <it>Porphyromonas gingivalis</it> infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice
by: Miyazawa Haruna, et al.
Published: (2012-09-01)

Knowns and unknowns in the care of pediatric familial hypercholesterolemia
by: Andrew C. Martin, et al.
Published: (2017-09-01)

Counterpoint: Flexibilization of Fasting for Laboratory Determination of the Lipid Profile in Brazil: Science or Convenience?
by: Maria Cristina de Oliveira Izar

Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside
by: Agarwala A, et al.
Published: (2021-05-01)

Inclisiran in lipid management: A Literature overview and future perspectives
by: Pietro Scicchitano, et al.
Published: (2021-11-01)

Advances on the treatment of Dyslipidaemias
by: Eleni Bilianou
Published: (2017-01-01)

Retargeting the management of hypercholesterolemia – focus on evolocumab
by: Colletti A, et al.
Published: (2016-09-01)

Cannot write session to /tmp/vufind_sessions/sess_3v01h95mk0tvh1st87kf22d6m1